Cetuximab in refractory metastatic colorectal cancer: Analysis of efficacy and response by patient and disease variables

3671 38 metastatic CRC patients refractory to oxaliplatin- and irinotecan-regimens were treated with single-agent cetuximab in two research studies, an open-label phase II investigation and an Expa...